Kinetics of NAbs in patients with MM. Nabs at at 1 month after the second dose of the BNT162b2 (median, 58.4%; IQR, 24.5% to 89.4%; day 50), at the time of the third dose (median, 27.1%; IQR, 13.9% to 65.8%; before third dose), and at 1 month after the booster dose (median, 96.7%; IQR, 52.6% to 97.8%). A significant reduction in NAbs was shown between day 50 and the time of third dose (P < .001); however, a significant increase in NAbs was evident at 1 month after the booster dose (P < .001).